Active Biotech Interim Report Q3 2022
THIRD QUARTER IN BRIEF
- Based on the authorization from the general meeting, the board of directors resolved to carry out a rights issue of approximately SEK 55 million to secure financing of the ongoing and planned development programs (Aug 4)
- The first part of the multiple dose of laquinimod eye drops in the phase I study has been completed without any serious side effects that can be linked to laquinimod and the study has been expanded with another dose group
- Active Biotech announces final outcome of the company’s rights issue (Sep 7)
EVENTS AFTER THE END OF THE PERIOD
- Active Biotech further strengthens the patent protection for laquinimod in eye disorders with a granted patent in US (Oct 24)
Financial summary
| SEK M | Jul-Sep | Jan-Sep | Full year | ||
| 2022 2021 | 2022 2021 | 2021 | |||
| Net sales | – | – | – | – | – |
| Operating profit/loss | -13,4 | -11,3 | -42,6 | -33,6 | -49,8 |
| Profit/loss after tax | -13,4 | -11,2 | -43,4 | -33,7 | -49,8 |
| Earnings per share (SEK) | -0,06 | -0,05 | -0,19 | -0,16 | -0,24 |
| Cash and cash equivalents (at close of period) | 55,0 | 68,4 | 53,1 | ||
The report is also available at www.activebiotech.com.